- Home
- CHPT vs CCCC Comparison
CHPT vs CCCC Comparison
Compare CHPT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- CCCC
- Stock Information
- Founded
- CHPT 2007
- CCCC 2015
- Country
- CHPT United States
- CCCC United States
- Employees
- CHPT N/A
- CCCC N/A
- Industry
- CHPT Industrial Specialties
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- CHPT Consumer Discretionary
- CCCC Health Care
- Exchange
- CHPT Nasdaq
- CCCC Nasdaq
- Market Cap
- CHPT 483.4M
- CCCC 396.0M
- IPO Year
- CHPT N/A
- CCCC 2020
- Fundamental
- Price
- CHPT $1.24
- CCCC $3.95
- Analyst Decision
- CHPT Hold
- CCCC Buy
- Analyst Count
- CHPT 13
- CCCC 6
- Target Price
- CHPT $2.51
- CCCC $10.67
- AVG Volume (30 Days)
- CHPT 18.6M
- CCCC 1.9M
- Earning Date
- CHPT 12-04-2024
- CCCC 10-31-2024
- Dividend Yield
- CHPT N/A
- CCCC N/A
- EPS Growth
- CHPT N/A
- CCCC N/A
- EPS
- CHPT N/A
- CCCC N/A
- Revenue
- CHPT $431,026,000.00
- CCCC $33,668,000.00
- Revenue This Year
- CHPT N/A
- CCCC $75.79
- Revenue Next Year
- CHPT $15.02
- CCCC N/A
- P/E Ratio
- CHPT N/A
- CCCC N/A
- Revenue Growth
- CHPT N/A
- CCCC 65.45
- 52 Week Low
- CHPT $1.05
- CCCC $3.61
- 52 Week High
- CHPT $2.68
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- CHPT 51.77
- CCCC 41.77
- Support Level
- CHPT $1.13
- CCCC $3.61
- Resistance Level
- CHPT $1.30
- CCCC $4.06
- Average True Range (ATR)
- CHPT 0.11
- CCCC 0.44
- MACD
- CHPT -0.00
- CCCC 0.01
- Stochastic Oscillator
- CHPT 32.05
- CCCC 22.82
About CHPT ChargePoint Holdings Inc.
ChargePoint designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.